ATTENTION !! Dear Readers, BHAVIKK SHAH's BLOG is totally free website. Contents here should be viewed for Knowledge purpose only. Author does not charge for any kinds of the services. Kindly don't entertain to any of the paid services in a name of BHAVIKK SHAH's BLOG !!
Showing posts with label IPO. Show all posts
Showing posts with label IPO. Show all posts

Saturday, January 21, 2017

BOMBAY STOCK EXCHANGE LTD (BSE LTD) : IPO MUST SUBSCRIBE !!!

Price Band: Rs. 805 - Rs. 806.
Retail Discount : NA .
Face Value: Rs. 2.00.
Minimum Lot Size: 18 Shares.
Issue opens on: 23rd January 2017, Monday.
Issue closes on: 25th January 2017, Wednesday.
Listing Date on: 3rd February 2017.
Listing on: NSE onlyScript Code: BSE
Total No. of Shares offered: 1,54,27,197 shares or 28.26 %.
Employee Reservation: NA. 
QIB Book: 77,13,598 shares or 50 % of issue. 
Non – Institutional Bidders: 23,14,079 shares or 15 % of issue.
Retail Book: 53,99,518 shares or 35 % of issue.
Equity Shares outstanding prior Issue: 5,45,88,172 shares.
Equity Shares outstanding post Issue: 5,45,88,172 shares.
Total Size of the Issue: Rs. 1,243.43 Crs - Rs. 1,241.89 Cr.

KEY FINANCIALS* 31 Mar 1431 Mar 1531 Mar 1630 Jun 16
Total Income (₹ Crs)266.79361.14426.54113.02 
Net Profit (₹ Cr)135.19129.74122.5341.40
Net Profit Margin (%)25.5020.8018.6023.30
EPS (.)12.7811.8811.223.79
NAV (.)224.11225.33224.27228.06
Net Worth (.)2,370.772,460.892,449.282,490.68
ROE (%)5.805.40 5.00 6.70
ROCE (%)9.708.708.20  9.70
*Standalone nos. & figures before consolidation of share capital from Re. 1 to Rs.2

BOMBAY STOCK EXCHANGE LIMITED: BSE was founded in 1875 and is Asia’s oldest stock exchange and is based in Mumbai, India. The company was formerly known as Bombay Stock Exchange Limited and changed its name to BSE Limited on July 2011. BSE Ltd incorporated itself as company limited by shares from the Association of person on 20th May 2005, under the demutualization scheme introduced by the market regulator SEBI (Securities and Exchange Board of India) whereby the 700 odd brokers shareholders surrendered their membership cards in exchange for the shares, whereby BSE members were alloted 10,000 Shares of Re.1 each against 1 membership right held. In November 2008, BSE gave handsome bonus in ratio of 12 new shares of Re.1 each for every 1 share of Re.1 held to its members. In 25th Novemeber 2016 company declared consolidation of Share capital by increasing the nominal value of Equity shares from Re. 1 per share to Rs. 2 per share. BSE was the first Exchange in India to be recognized as a Stock Exchange by the Government of India under the Securities Contracts (Regulation) Act, 1956. BSE Limited, together with its subsidiaries, provides market platform for trading in equity, debt instruments, derivatives, and mutual funds in India. It  also offers depository and record-keeping services to the securities industry that facilitate dematerialization of holding of securities and book entry settlement, clearing and settlement functions for trades reported on the debt and mutual fund segments of the company and for the currency derivatives segment on United Stock Exchange, as well as collateral management and risk management services for various segments of stock exchanges. In addition, the company provides education services through BSE Institute Ltd and IT solutions with focus on equity, stock, commodities, banking, and financial services markets that include a multi-asset online collateral management system; a clearing and settlement system for delivery-based derivatives; real time risk management system with integrated collateral management system software. Company has two prominent subsidiaries namely Central Depository Services (India) Ltd (CDSL), Indian Clearing Corporation Ltd (ICCL), Marketplace Technologies Pvt Ltd (MTPL), BFSI Sector Skill Council of India (BFSI), Marketplace Tech Infra Services Pvt Ltd, CDSL Ventures Ltd (CVL), Central Insurance Repository Ltd (CIRL) and lastly BSE Institute Ltd (BIL).

Company’s product Fastrade on Web allows investors to trade online on the company, as well as on NSE; BSE's settlement software handles settlement pertaining to various segments of the company and an end-to-end system helps for offer for sale; BSE StAR MF, an online mutual fund transaction platform; and a platform for trading in equities of small-and-medium enterprises. In Janaury 9, 2017, BSE inaugarated India's first International Exchange (INX), in Gujarat's International Financial Services Centre (IFSC) in Gujarat International Finance Tech (GIFT) City- Gujarat. India INX is a state-of-the-art facility, which will act as a gateway to raise capital for the country's infrastructure and development needs, it also provides cross broder opportunities of investment with a comparatively low cost of transaction in the world. India INX provides advantages in terms of Tax Structure and supportive regulatory framework - which includes No Security transaction tax, No commodity transaction tax, No dividend distribution tax, No long term capital gain tax and No Income tax for first five years. On February 19, 2013, BSE and S&P Dow Jones Indices announced an strategic partnership to calculate, disseminate and license the widely followed suite of BSE indices. Each of the BSE indices will be co-branded as "S&P" including the S&P BSE SENSEX, BSE 200, BSE 100. BSE Ltd is earliest and second biggest exchange from 22 stock exchanges in India with more than 5,600 stocks listed on its platform. It accounts for over two thirds of the total trading volume in the countryApproximately 70,000 deals are executed on a daily basis, giving it one of the highest per hour rates of trading in the world. BSE has 5,672 companies listed which makes BSE first exchange to have most of the listed companies around the globe and among these there are around 3,500 companies which have a serious trading volume. The combine market value of these companies is Rs. 99 trillion. This makes BSE 11th largest on planet. The BSE `Sensex' is a widely used market index and is a value-weighted index composed of 30 companies with the base of April 1979 = 100. In 2011, BSE improved its technology & its response time to each trade improved to 10 milliseconds against 200 milliseconds earlier. As a result it gained higher order to transaction ratio. The ratio was at 19:1 - means there were 19 trades against 1 transaction, this was much higher then the benchmark, this had provide ample liquidity and attracted algorithm trades. BSE in June 2013, bought a technology from Germany's Deutsche Borse to speed up its execution of trades on its exchange. This new technology helped BSE to execute 1 lakh orders per second as compared to 20,000 order per second currently. This technology has increased the speed response of BSE systems by 100 times from the currently around 10 milliseconds to 100 microseconds. At present BSE can handle 1,00,000 orders a second against 20,000 earlier. BSE is compared with MCX of India locally and Globally it is compared with Bursa Malaysia Berhad of Malaysia; Singapore Exchange Ltd of Singapore; Japan Exchange Group Inc of Japan; CME Group Incorporation, NYSE Euronext, Nasdaq OMX Group Inc.(The) and Intercontinental Exchange Inc of USA. 

Valuations:
The company has fixed the price band at Rs. 805-806 per share. FY16 consolidated total income increased 5 % YoY to Rs. 658 Cr, PBT before exceptional items was Rs. 238 Cr and PAT was Rs. 123 Cr. For H1FY17 the consolidated total income improved to Rs. 383 Cr and PAT came in at Rs. 105 Cr. BSE will sell 24 % in CDSL in IPO in FY17 which will reduce topline by about Rs. 120 Cr to BSE and reduction in PAT by Rs. 20 Cr for BSE in FY18. But, Bse will also get benefitted with no more expenses on Liquidity Enhancement scheme which was about Rs. 250 Cr and with SEBI now directing BSE not to transfer 25 % of its profit to settlement gurantee fund will boost bottomline forward. Based on FY16 annual EPS of Rs. 22.44 (post consolidation of share capital), BSE issue is priced at P/E of 35.87x on lower band and 35.91x on upper band. This is at a significant discount to peers like MCX which is trading at 47 times. BSE has consistently maintained high PAT margin with strong ROE of 34 %. It is a debt free company with consolidated Net-worth at Rs. 2,553 Cr which translates in Book value of Rs. 468 per share. BSE has cash and cash equivalents of Rs. 2,492 Cr which translates cash per share of Rs. 456.50. For BSE its 85 % of its revenue comes as trading fees and charges. BSE has a robust cash flows with fantastic return ratios.

Comparisons with Industry globally as on 20 Jan 2017 
Exchange
Currency
Price
O/S Shares (Cr) 
MarketCap (Cr)
Basic EPS 
NAV
P/E
RONW(%)
BSE
INR
806
5.458
64.52
22.44
468
35.91
9.70
MCX
INR 
1193.15
5.10
89.41
25.79
272.92
46.31
3.50
CME Grp
US $
116.66
33.67
3,929
4.29
61.07
27.21
6.01
ICE
US $
57.40
11.344
3,425
2.44
25.06
23.49
9.38
ASX
AUD $
48.99
19.35
948
2.20
19.59
22.23
11.24
NZX
NZD $
1.06
26.83
28.441
0.03
0.29
30.42
37.52
LSG
GBP
3,018.38
0.35
1,057
0.68
790.15
44.26
9.85
SGX
SGD $
7.53
107.17
807
0.31
0.93
24.30
35.51
HongKong Exg 
HKD $
185.50
122.43
22,711
4.99
25.34
37.18
31.15

Outlook and My views on IPO:
According to me one should look for subscribing for BSE IPO as it enjoys to be in the oligopoly nature, high operating leverage, robust cash flow and is in business which has high entry barrier. BSE will be second listed company after MCX - the National stock Exchange of India  is unlisted. Most of the BSE's revenue comes from retail traders. About 10 % of revenue comes from Institutions, about 25 % from Algorithmic trading and the rest comes from Retail traders. 85 % of its revenue coming from rating business which earns better margins is thus being offered to public at very attractive valuation. BSE has a market share of 39 % in the currency derivates segment and 14 % in equity cash segment whereas NSE remains the leader with market share of 56 % and 86 % respectively. BSE distributes 85 % of its profit as dividend and plans to continue with high dividend in future, BSE has filed IPO for its subsidiary CDSL and would be dilute 26 % stake in the IPO. The Information and data services of BSE contributes 4 % to 5 % as compared to 10 % to 25 % in other economies. They gre at 14 % CAGR over 5 years, for BSE there is ample of scope and should grow annually by atleast 15 %. Revenues from Index services can grow if it is expanded its offering beyond equities and hence revenue from Index Services should grow at 15-20 % over the next 5 years (as per DRHP). The best way to participate in the growth of a nation is to own a piece of its stock exchange, because the best and most profitable commercial ideas eventually become publically listed companies. Exchanges in India are still in development phase and has ample headroom for growth in retail participation. Equity as percentage of financial savings in India ia at a remarkably low level of 5 % in contrast with 14 % in China, 15 % in Brazil, 20 % in Indonesia and 42 % in USA. This will increase as goverment is mulling to boost equity investment in India via allowing EPFO to invest in equity, new products like REITs. India is a fantastically diverse country with an unrivalled entrepreneurial culture. Listing on the BSE, which hosts more than 5,300 companies than any exchange in Asia, provides the capital to empower those businesses to expand. Exchanges are almost the perfect business models with limited competition, high operating leverage and robust cash flows. Stock exchanges in particular have strong correlation to underlying economic activity. In India only two exchanges accounts for nearly 99 % market share in equities trading. Across a number of macroeconomic and broad market factors the Indian capital markets are at a “multiyear to multi decade low”. Stock exchanges would benefit substantially from the anticipated improvement in overall economic activity there by leading to high earnings growth over the next few years. NSE the Unlisted and BSE also Unlisted along with the MCX-SX which is also unlisted but directly related to MCX will be one of the best investments to play the impending recovery in economy and capital markets. India is already seeing initial signs of volume recovery with last two months & cash market volumes are up 100 % YoY. At current levels the velocity is in-line with eight year average of 60 %. Moreover with a number of new products having high potential (such as Interest Rate Derivatives, Corporate Debt, Volatility Index) in their nascent stages, exchanges would have robust volume growth over the medium term. 

Globally, Exchanges trends to trade at average of 5 times their book value and at 18-20 times their earnings. Indian stock exchanges are comparable to their Asian peers than their western peers. Western market exchanges are not vertically integrated (Depository and Clearing Corporation not part of the exchange) and hence do not have the float income enjoyed by vertically integrated exchanges. Emerging market Asian exchanges such a Hong Kong stock Exchange and SGX trade at 25x 1 year forward P/E & 13x EV/EBITDA. It can be safely assumed that NSE could command similar valuation given its market leadership, track record in launching new products and potential for growth. BSE is at a cusp of a turn-around, with the all the ingredients such as focus on increasing market shares in various segments, innovation, technology, infrastructure and management in place. It can be noted that a small shift in market share is adequate for BSE to have sharp increase in earnings. The Top 5 subsidiaries of BSE which are CDSL- 50.1 %; ICCL-100 %; Marketplace Technologies-100 %; CDSL Venture- 100 %; BSE Institute-100 %, and all are profitable. At the IPO price of Rs. 806, BSE will have Market cap of Rs. 4,399.80 Cr (5,45,88,172 shares x Rs. 806) which means a P/E of 35.87 times for FY16 and P/E of 21 times for FY17E. BSE to have enterprise value of Rs. 1,907 Cr at upper price band of Rs. 806. Thus, on valuation excluding cash & value of CDSL holding BSE's stock exchange business is available at Rs. 1,100 Cr which is attractive pricing & with new business coming up in INDIAINX in gift city strong fundamentals with good institutional holdings the Long term investors should look into subscribing the IPO for good opportunity. Short term investor can subscribe for listing gains.

*
As the author of this blog I disclose that I do hold BSE LIMITED at pre ipo in my investment portfolio.

* READ PREVIOUS POSTS ON BSE - CLICKHERE

**Dear Reader Friends, if you enjoyed this article then please do share it with your friends & colleagues through Facebook and Twitter, also do drop in your valubale thoughts in comment box...
So, grab a fresh hot cup of coffee, turn on your net & browse on to www.bhavikkshah.blogspot.in & take out few minutes to get to know the most interesting world of investment... Till then HAPPY INVESTING, don't forget to Share !! 

-------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------
Disclaimer
This is a personal blog and presents entirely personal views on stock market. Any statement made in this blog is merely an expression of my personal opinion. These informations are sourced from publicly available data. By using/reading this blog you agree to (i) not to take any investment decision or any other important decisions based on any information, opinion, suggestion, expressions or experience mentioned or presented in this blog (ii) Any investment decisions taken if any would be his/hers sole responsibility. (iii) the author of this blog is not responsible. 


As a Disclosures I Confirm that : 
I confirm that I shall not deal or trade in securities mentioned in this article within thirty days before and five days after the publication of this article. I also confirm that I will not deal or trade directly or indirectly in securities mentioned in this article in a manner contrary to the ideas put forth in the article. I have not received any financial compensation for writing this article.
 

---------------------------------------------------------------------------------------------
---------------------------------------------------------------------------------------------

READ HERE TO KNOW MORE ON LONG TERM INVESTING - CLICK HERE

VIEW THE POWER POINT PRESENTATION ON

Monday, July 27, 2015

SYNGENE INTERNATIONAL LTD: SUBSCRIBE THIS IPO !!!

Price Band: Rs. 240 - Rs. 250.
Retail Discount : NA . 
Face Value: Rs. 10.00. 
Minimum Lot Size: 60 Shares. 
Issue opens on: 27th July 2015, Monday. Issue closes on: 29th July 2015, Wednesday.
Listing Date on: by 14th August 2015.
Total No. of Shares offered: 2,20,00,000  shares or 11.00 %.
Biocon Shareholders Reservation: 20,00,000 shares of total issue.
Net Public Offer: 2,00,00,000 shares.
QIB Book: 1,00,00,000 shares or 50 % of issue.
Anchor Investor Portion: 60,00,000 shares of QIB
For Mutual Funds Portion: 2,00,000 shares of QIB
Balance for all QIB including Mutual Funds: 35,00,000 shares of QIB
Non – Institutional Bidders: 30,00,000 shares or 15 % of issue.
Retail Book: 70,00,000 shares or 35 % of issue.
Equity Shares outstanding prior Issue: 20,00,00,000 shares.
Equity Shares outstanding post Issue: 20,00,00,000 shares.
Total Size of the Issue: Rs. 528.00 Crs - Rs. 550.00 Cr.
IPO GRADING: Strong Fundamentals
FAIR VALUE RANGE - Rs. 320 - Rs. 340.

KEY FINANCIALS31 Mar 1131 Mar 1231 Mar 1331 Mar 1431 Mar 15
Sales (Cr)322.00417.00550.00700.00860.00
Net Profit (Cr)27.0071.00102.00135.00175.00
Net Profit Margin8.38 %17.02 %18.54 %19.28 %20.34 %
EPS (.)1.403.605.106.708.80
NAV (.)11.0014.8025.9033.0043.70
Net Worth (₹Cr)220.70296.80518.60659.30844.90
ROE (%)12.3323.9219.7020.5020.70
ROCE (%)7.4018.0019.7016.6017.50
*Thee face value of company was Rs. 5 and then it consolidated its face value to Rs. 10 on March 16, 2015.

SYNGENE INTERNATIONAL LIMITED: 
Incorporated in 1993 and headquartered in Bengaluru, Syngene International Limited is a subsidiary of Biocon Limited, a global biopharmaceutical enterprise focused on delivering affordable formulations and compounds. Biocon, owns about 85 % of Syngene, and will reduce its stake to about 74 % through the IPO. Syngene International Ltd is one of the leading Indian-based contract research organizations, offering a suite of integrated, end-to-end discovery and development services for Novel Molecular Entities (“NMEs”) across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. Company’s service offerings also support the development of biosimilar and generic molecules. In the near term, it intends to forward integrate into commercial-scale manufacturing of NMEs. As an experienced CRO with a proven track record of providing quality NME discovery, development and manufacturing services and continued focus on reliability, responsiveness and protection of client’s intellectual property, Syngene is well-positioned to benefit from the expected growth in the CRO industry The company offers services through flexible business models that are customized to their client’s requirements. During Fiscal 2015, Syngene serviced 221 clients, ranging from multinational corporations to startups, including 8 of the top 10 global pharmaceutical companies by sales for 2014. It has several long-term relationships and multi-year contracts with their clients, including three long-duration multidisciplinary partnerships, each with a dedicated research centre, with three of the world’s leading global healthcare organizations Bristol-Myers Squibb Co. (“BMS”), Abbott Laboratories (Singapore) Pte. Ltd. (“Abbott”) and Baxter International Inc. (“Baxter”).

SOME FACTS ON SYNGENE:
Syngene provides contract drug discovery, research and manufacturing services to 17 of the world's top 20 pharmaceutical companies, including Bristol Myers Squibb & Co and Abbott Laboratories Ltd. Its revenue rose 25 % in the last three years. It manages a pool of 2,122 scientists including 258 PhDs and 1,665 scientists with master’s degree, to ensure timely execution of projects, cost effectiveness and quality of the projects, confidentiality and protection of intellectual property. The company owns state-of-the-art research facilities spread over 900000 sq. ft., certified by major regulatory bodies. As an experienced CRO, Syngene is well positioned to capitalize on the advantages of its flexible business models that customizes to their client’s requirements globally. There are great opportunities for CROs from the outsourcing markets and thus increasing their share towards global R&D expenditures. The company’s increasing clientele, expanding capacities as well as capabilities, along with plans for forward integration into commercial manufacturing will enable the company to drive growth by benefiting from the opportunities in future. Syngene is well poised to cash in on growing global pharma R&D outsourcing trend. Global pharmaceutical players are facing structural issues such as profit pressures arising from impending patent cliff, drying product pipeline and rising R&D costs. Surprisingly, however, the new product approvals from the USFDA are on the rise. Hence to maintain the cost balance at one end and maintain the new product introduction at the other, these players are inclined to outsource some of the R&D budget to CROs like Syngene. The parent Biocon is looking for a demerger may be considered when Biocon is less financially dependent on Syngene.

OUTLOOK:
The global CRO market for discovery services was estimated at US$14.7 billion in 2014 and is expected to reach US$22.7 billion in 2018, reflecting a CAGR of 11.5 % (2014-18), according to the IQ4I Report. The global CRO market for development services was estimated at US$28.8 billion in 2014 and is expected to reach US$44.6 billion in 2018, reflecting a CAGR (2014- 18) of 11.6 %, according to the Frost & Sullivan Report. Contract research organisations (CROs) offer outsourced services to support discovery and development for R&D driven organisations across industrial sectors like pharmaceuticals, biotechnology, biopharmaceuticals, neutraceuticals, animal health, agro-chemicals, cosmetics and electronics. CRO services span the range of R&D activities from new molecular entity (NME) discovery, development and manufacturing. Growth in the CRO market has historically been driven by growth in R&D spending and increased outsourcing of R&D activities. CROs offer clients an opportunity to manage costs, have flexible operations and realise efficiencies in R&D and related functions. Also, the need for greater flexibility has reduced the willingness of these players to incur large fixed costs associated with large scale R&D programmes. Outsourcing allows clients to convert a portion of their R&D budgets from a fixed to a variable cost, giving them greater flexibility to shift strategic and development priorities in response to market conditions. India has offered a significant cost advantage and skilled personnel. However, as global pharma outsources more R&D functions, outsourcing to India is increasingly seen as a strategic move to garner quality and value, rather than just a tactical decision to lower costs. High recall value Due to its integrated service offerings coupled with consistent performance and high data integrity ethos, Syngene has enjoyed high recall value, which is reflected from the fact that eight out of top 10 clients have been engaged with the company for the past five years. The company has also established dedicated centre for its three major clients Bristol-Myers Squibb Co (BMS), Abbott and Baxter. BMS has also recently extended this engagement with Syngene to 2020. Syngene stands to gain from forward integration to become a Contract Manufacturing Organization (CMO). Further, Syngene’s plan to foray into CMO of novel drugs will add significant upside over the next 3-4 years. Entry into the CMO business will open up the large revenue source (like Divi’s) and make Syngene a complete turnkey solution provider amongst the Indian bourses.

VALUATION:
Syngene is likely to incur capex of US $200mn in the next 2-3 years for greenfield as well as brownfield expansion. It currently manufactures small & large molecule to support clinical trials for multiple clients. It has shown healthy financial performance in the last 5 years. During the last 4 years, revenue grew 28 % and shown PAT CAGR of 59 %. During the same period its EBITDA grew by 31 %. In FY15, the company derived 96 % of revenue from the export market. During FY15, revenue grew 23 % YoY, to Rs. 860 crore, 95 % of which came via exports, while EBITDA margin was healthy at 34 %, leading to an EBITDA of Rs. 293 crore, up 32 % YoY. Since the company enjoys many tax concessions in form of SEZ unit and additional depreciation on plant and machinery, income tax rates are very low, and stood at just 14 % for FY15. Thus, net profit of Rs. 175 crore was earned in FY15, translating into net margin and EPS of 20.3 % and Rs. 8.89 respectively. On equity of Rs. 199 crore (face value of Rs. 10 each), company has net worth of Rs. 845 crore, as of 31st March 2015. While it has total debt of Rs. 155 crore, balance sheet shows current investments and cash balance of Rs. 262 crore, indicating net cash surplus of Rs. 107 crore, or Rs. 5.36 per share. At upper band of the IPO, Enterprise value of SYNGENE comes at Rs. 5,048 Cr and at lower band it comes at Rs.4,848 Cr. 

According to me one should look for subscribing for SYNGENE INTERNATIONAL LTD IPO, the company has fixed the price band at Rs. 240-250 per share. Based on FY15 annual EPS of Rs. 8.80, SYGENE is offered at P/E range of 27.27x on price of Rs. 240 and at a PE of 28.40x on price of Rs. 250. This Ipo is fairly valued given its operational scale. Extrapolating FY15’s earnings growth rates of 30 % to FY16, company is estimated to clock net profit of Rs. 228 crore for FY16 translating into EPS of Rs. 11.45 , which indicates a PE multiple of 21 times, at upper price band. PE multiple of 22 times, based on current year earnings, is attractive for a high-growth pharma stock clocking healthy margins, with a sound balance sheet, backed by strong management team and pedigree. Since Sun Pharma Advanced Research is loss making and there are no other pure-play CRAMs players listed on Indian bourses, no listed peer is ideal for comparison. Thus, with attractive pricing & strong fundamentals with good institutional holdings the Long term investors should look into subscribing the IPO for good opportunity. Short term investor can subscribe for listing gains.

As I always say, I am a long term believer in markets & I do respect the markets and will keep a strict stop loss of 8 % on every purchase(Why Strict stop loss of 8 % ?) - Click Here

*As the author of this blog I disclose that I do have applied for the IPO.

*Dear Reader friend, if you enjoyed this article, please do share it with your Friends and Colleagues through Facebook and Twitter, and drop in your valuable thoughts in comment box..

READ HERE TO KNOW MORE ON LONG TERM INVESTING - CLICK HERE

VIEW THE POWER POINT PRESENTATION ON

-------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------
Disclaimer
This is a personal blog and presents entirely personal views on stock market. Any statement made in this blog is merely an expression of my personal opinion. These informations are sourced from publicly available data. By using/reading this blog you agree to (i) not to take any investment decision or any other important decisions based on any information, opinion, suggestion, expressions or experience mentioned or presented in this blog (ii) Any investment decisions taken if any would be his/hers sole responsibility. (iii) the author of this blog is not responsible.
---------------------------------------------------------------------------------------------
------------------------------------------------------------------------------

Top post on IndiBlogger.in, the community of Indian Bloggers


Related Posts Plugin for WordPress, Blogger...

Share

Why you should have a Stop Loss of 8 % ? Click to know more. Author is also on Facebook and Click here for SHORT STORIES

X